Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Center Laboratories's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Center Laboratories's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Center Laboratories FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Center Laboratories's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Center Laboratories's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Center Laboratories (ROCO:4123) has a FCF Margin % of -2.74% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Center Laboratories and its competitors. According to the industry distribution chart, Center Laboratories ranks #355 out of 963 companies in the Drug Manufacturers industry, placing it in the top 36.9%.
Is Center Laboratories' FCF Margin % too high?
Center Laboratories' current FCF Margin % is -2.74%. Based on the distribution chart, Center Laboratories ranks #355 out of 963 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Center Laboratories has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Center Laboratories' FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Center Laboratories ranks #355 out of 963 companies for FCF Margin %. This puts Center Laboratories in the upper half of its industry. The industry median FCF Margin % is 2.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.57, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Center Laboratories and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Center Laboratories's current FCF Margin % is -2.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Center Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Center Laboratories (ROCO:4123) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$41.39, compared to a current price of NT$30.15 — trading 27.2% below its estimated fair value. The current FCF Margin % is -2.74%. Center Laboratories' overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Center Laboratories (ROCO:4123), the current FCF Margin % is -2.74% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Center Laboratories (ROCO:4123) Overvalued in 2026?
Based on GuruFocus' analysis, Center Laboratories stock appears to be undervalued.
The current stock price of NT$30.15 is trading 27.2% below its estimated GF Value™ of NT$41.39.
GuruFocus considers Center Laboratories to be Modestly Undervalued.
Key valuation signals for ROCO:4123:
FCF Margin %: -2.74%
GF Value™: NT$41.39 vs. price of NT$30.15 (27.2% below fair value)
No single metric tells the full story. See the ROCO:4123 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Center Laboratories Inc is engaged in the manufacture and sale of various Western pharmaceuticals, including Western medicine manufacturing, wholesale, and retail. The Company operates through the following segments: Pharmaceutical Division, Biotechnology Venture Capital, and Glac Segment. The Pharmaceutical Division, which generates the majority of revenue, manufactures and sells various Western pharmaceuticals. The Biotechnology Venture Capital segment invests in domestic and foreign biotechnology undertakings, while the Glac Segment manufactures and sells probiotic products. The Company operates in Taiwan, Mainland China, and other regions, with Taiwan generating the majority of revenue.
71GF Score
Get the complete analysis for ROCO:4123
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4123 has been successfully added to your 
